Work

FDA Evaluating Possible Serious Risks From Umbralisib

Year: 2022

Type: article

Source: AJN American Journal of Nursing

DOI: 10.1097/01.naj.0000833916.26417.b5

Author: Diane S. Aschenbrenner

Institutions: Johns Hopkins University, Notre Dame of Maryland University

Language: English

Topic: Pharmacovigilance and Adverse Drug Reactions

Subfield: Toxicology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281566111

FWCI: 1.024

Cites:

Cited by: 7

Related to: 10